依普利酮价格

(Inspra) is a new type of selective aldosterone receptor antagonist that was approved for clinical use by the State Food and Drug Administration in 2002. It has stronger aldosterone antagonism than spironolactone and has extremely low affinity for androgen and progesterone receptors. Aldosterone has a variety of pathophysiological effects, including causing central hypertension, accelerating endothelial damage (catecholamines enhance its effects), reducing heart rate variability, inducing ventricular arrhythmia, promoting sodium retention, potassium and magnesium loss, promoting myocardial fibrosis, necrosis and inflammation, and damaging the fibrinolytic system. Eplerenone has fewer side effects and is well tolerated, making it a good alternative to spironolactone.

The EPHESUS trial showed that for patients with left ventricular ejection fraction (LVEF) <40% and heart failure within 3 to 14 days after myocardial infarction, adding eplerenone (Inspra) to standard treatment can reduce all-cause death by 15%, primary combined endpoint events (cardiovascular death or hospitalization due to cardiovascular events) by 17%, and sudden cardiac death by 21%.

Eplerenone is not currently approved for marketing in China, so you can only buy overseas drugs. However, the price of the original drug is relatively high. The original drug of eplerenone (Inspra) in the United States is available in two specifications, 25mg-30 tablets/box, priced at about 118.71 US dollars; 50mg-30 tablets/box, priced at about 124.09/USD.

More and more patients are choosing to buy the Indian version. The price of eplerenone (Inspra) in India is as follows: the specification is 50mg*100 tablets, and the price is around $500. Due to the influence of exchange rates and other factors, the price is not fixed. Please consult Medical Travel for specific prices.

Recommended related hot articles: /newsDetail/72971.html